Key Investor Signals
Raised £1.5M pre-seed led by Science Creates’ SCVC
Houdini Bio raised £1.5M in June 2026 in a pre-seed round led by SCVC, the venture arm of Science Creates, to develop ARCANA for gene and cell therapy applications.
Reported 4–5x higher protein output per dose
The company reports 4–5x more protein per dose after redesigning a haemophilia A gene therapy construct in liver cells, supporting lower-dose potential.
Built on Cambridge-discovered anti-silencing rules
CEO Jonathan Cohen-Gold identified DNA design rules that evade HUSH during his Cambridge PhD in the laboratory that discovered the silencing system.
Other Positive Signals
- Co-founder Lee Dunham spent seven years at the Cell and Gene Therapy Catapult, most recently as Director of Business Development.
- Published ARCANA’s first public technical description in July 2026, outlining its anti-silencing DNA design approach.
- Named a Falling Walls Venture TOP 100 Science Startup for 2026.
- Completed the six-month KQ Labs accelerator at the Francis Crick Institute and presented at its July 2026 Demo Day.
Team
Jonathan Cohen-Gold
Co-founder and CEO
- Completed a Cambridge PhD in molecular medicine, where he identified the DNA design rules underlying Houdini Bio’s platform.
- Led Cambridge research on sustaining expression from delivered genes, directly matching the problem Houdini Bio now commercializes.
- Investment Associate at Deep Science Ventures from 2023 to 2025, focused on building science-based startup opportunities.
Lee Dunham
Co-founder and Chief Business Officer
- Spent seven years at the Cell and Gene Therapy Catapult, latterly as Director of Business Development from 2023 to 2025.
- Supported spin-out formation and health and life-science IP commercialization at the University of Liverpool’s Business Gateway.
- Conducted due diligence on academic inventions and identified licensees and investors as an Intellectual Property Fellow at UMIP.
Product
Houdini Bio’s ARCANA platform redesigns therapeutic DNA sequences to reduce cellular silencing without changing the encoded protein. Machine-learning models apply anti-silencing design rules to predict sequence variants more likely to maintain expression.
Redesigns DNA, preserves the protein
ARCANA rewrites the DNA sequence while preserving the protein it encodes. It removes sequence features associated with silencing rather than changing the therapeutic payload or biological target.
Works with existing delivery systems
ARCANA changes the therapeutic DNA sequence rather than the vector or delivery route. The company says it can work with a developer’s existing vehicle, target cell, and manufacturing process.
Gene, cell and manufacturing uses
The company says ARCANA is agnostic to payload and target cell, allowing the same sequence-design approach to be applied across gene therapy, cell therapy, and biomanufacturing programs.
Market Overview
Durability remains a major constraint in gene therapy. In haemophilia patients studied years after treatment, about one in four liver cells still carried the vector but only one in twenty-five expressed it. This shows that therapeutic DNA can persist after its activity falls, increasing pressure to use higher doses.
The potential customer base spans the broader cell and gene therapy sector. The Alliance for Regenerative Medicine counted 1,856 developers and 2,130 clinical trials worldwide at the end of 2025, while the global gene therapy market is projected to grow from $8.8B in 2026 to $18.2B by 2030.
In a primate liver study, protein levels fell sharply within three months even though vector DNA remained in the cells.
Years after haemophilia gene therapy, about 1 in 4 liver cells carried the vector but only 1 in 25 still expressed it.
Projected global market growth from 2026 to 2030, equal to an 18.9% CAGR.
Developers active worldwide at the end of 2025, collectively running 2,130 clinical trials.
Comparable Outcomes
Aldevron
Aldevron supplied plasmid DNA, mRNA and proteins used across gene and cell therapy programs, selling enabling inputs to biotech and pharma rather than developing therapies itself. Danaher acquired Aldevron in August 2021 for approximately $9.6B; the company had generated about $300M of revenue in 2020.
Brammer Bio
Brammer Bio developed and manufactured viral vectors for gene therapy developers, supporting more than 100 projects including first-in-human programs. Thermo Fisher acquired Brammer Bio in May 2019 for about $1.7B; the business was on track for $250M of annual revenue.
Interested in More Startups Like Houdini Bio?
Get a curated pipeline of healthcare and life sciences startups aligned with your investment thesis.
Sources
This profile was built from public company materials, ecosystem sources, market references, and professional profiles.